Update: Advancing CNS-penetrant ATR inhibitors with Enki™
Building on their initial hit series, Variational AI and Rakovina Therapeutics share promising new results on ATR inhibitors generated with Enki. The latest findings reveal compounds that balance potency, selectivity,… Read More about Update: Advancing CNS-penetrant ATR inhibitors with Enki™
Variational AI Enters Collaboration with Merck to Apply Generative AI to Drug Discovery
Variational AI, a generative AI drug discovery company, announced a collaboration with Merck, known as MSD outside of the United States and Canada, to apply Variational AI’s Enki™ platform to… Read More about Variational AI Enters Collaboration with Merck to Apply Generative AI to Drug Discovery
Variational AI & Life Chemicals join forces to discover selective dual EGFR/FGFR1 inhibitors using generative AI
Following their successful 2022 collaboration, which targeted the SARS-CoV-2 main protease, Variational AI and Life Chemicals have partnered for a second time to discover de novo generated selective dual EGFR/FGFR1… Read More about Variational AI & Life Chemicals join forces to discover selective dual EGFR/FGFR1 inhibitors using generative AI
Variational AI Joins Agora Open Science Trust to Advance PRMT6 Inhibitors for SBMA
Variational AI is proud to announce its participation in a new open science drug discovery initiative led by Agora Open Science Trust. The project is focused on optimizing the potency… Read More about Variational AI Joins Agora Open Science Trust to Advance PRMT6 Inhibitors for SBMA
Variational AI Named “Emerging Company of the Year – Biotech” by Life Sciences BC
Variational AI is proud to announce that it has been named Emerging Company of the Year – Biotech by Life Sciences BC. This award highlights Variational AI’s innovation in developing… Read More about Variational AI Named “Emerging Company of the Year – Biotech” by Life Sciences BC
Variational AI and Oncocross to Collaborate on AI-Driven Drug Discovery Program in Atopic Dermatitis
Variational AI announces a co-development agreement with Oncocross, to co-develop a novel small molecule inhibitor for chronic skin inflammation focusing on atopic dermatitis. Read More about Variational AI and Oncocross to Collaborate on AI-Driven Drug Discovery Program in Atopic Dermatitis
Accelerating the Discovery of Brain-Penetrant ATR Inhibitors with Enki™
Variational AI partnered with Rakovina Therapeutics to support the discovery of a brain-penetrant ATR inhibitor using our Enki™ generative AI platform. By generating and prioritizing novel, CNS-targeting compounds aligned with… Read More about Accelerating the Discovery of Brain-Penetrant ATR Inhibitors with Enki™
Variational AI Announces Oversubscribed $5.5 Million Financing to Launch Foundation Model for Small Molecule Drug Discovery
New funding to fuel market expansion of compute efficient foundation model for biopharmaceutical companies Read More about Variational AI Announces Oversubscribed .5 Million Financing to Launch Foundation Model for Small Molecule Drug Discovery
How to drug a novel target in 500 molecules
Research conducted by the Variational AI team: Marshall Drew-Brook, Peter Guzzo, Ahmad Issa, Mehran Khodabandeh, Sara Omar, Jason Rolfe, and Ali Saberali. Searching through the space of synthesizable molecules to find an… Read More about How to drug a novel target in 500 molecules
